TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05899387

Intervention type: PROCEDURE
Intervention: Swap collection
Description: Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site.

Intervention type: PROCEDURE
Intervention: Swap collection
Description: Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site.

Intervention type: PROCEDURE
Intervention: Swap collection
Description: Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site.

Intervention type: PROCEDURE
Intervention: Swap collection
Description: Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site.

Intervention type: PROCEDURE
Intervention: Seroma punction
Description: Puncturing of a seroma in case of occurence and clinical need

Intervention type: PROCEDURE
Intervention: Seroma punction
Description: Puncturing of a seroma in case of occurence and clinical need

Intervention type: PROCEDURE
Intervention: Seroma punction
Description: Puncturing of a seroma in case of occurence and clinical need
Study: NCT06449560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practice Group
Description: Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Group
Description: Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Feedback Group
Description: Participants receive the traditional core course (as the same in the practice group) along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
Study: NCT05657158

Intervention type: OTHER
Intervention: Brolucizumab
Description: Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
Study: NCT04637529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S (+) - Ibuprofen
Description: S (+) - Ibuprofen + placebo of Ibuvix®
Study: NCT06089499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Palliative Care: four educational learning module videos
Description: Organizational Sponsored public domain educational videos
Study: NCT05882942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Matcha green tea
Description: This is the condition with the Matcha green tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is the condition with the placebo
Study: NCT04637529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuvix® - ibuprofen
Description: Ibuvix® + placebo of S(+) - Ibuprofen
Study: NCT05448456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1 gram of tranexamic acid in 100 ml of 0.9% normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of 0.9% normal saline
Study: NCT06101173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)
Description: 1 dose of VLP-Polio vaccine (0.5ml) on Visit 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliomyelitis vaccine (IPOL)
Description: 1 dose of IPOL vaccine (0.5ml) on Visit 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio
Description: 1 dose of VLP-Polio vaccine (0.5ml) on Visit 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPOL
Description: 1 dose of IPOL vaccine (0.5ml) on Visit 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio
Description: 1 dose of VLP-Polio vaccine (0.5ml) on Visit 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPOL
Description: 1 dose of IPOL vaccine (0.5ml) on Visit 1
Study: NCT06644040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TeriQ Patch
Description: Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch
Study: NCT06488079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summary Label
Description: The Nutri-Score Front-of-Pack nutritional label
Study: NCT06644040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teribone Inj.
Description: Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forteo Inj.
Description: Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection
Study: NCT05320978

Intervention type: DEVICE
Intervention: Hand grip test, computed tomography
Description: A hand grip test, abdominal computed tomography are performed before surgery.
Study: NCT06284759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post-discharge telenursing intervention
Description: Tele-nursing based on Orem's Self-Care Theory was applied to patients with lower extremity fracture surgery. Phone/video calls 24-48 after discharge. hours, 7-10. day,18-21. day, 28-30th day and 40-45th day. day was made. Telephone or video conference interviews were held on the day and time convenient for the patient. After each meeting, the date and time of the next meeting was planned. The video conferencing method (zoom, skype, whatsapp, etc.) was presented to the patient's preference and the decision was made together. In phone/video conference calls, patients were informed about their current problems. Additionally, patients' questions were answered. Prior to tele-nursing monitoring, the researchers identified emergent or urgent situations; Patients were informed that they should consult their doctor if this occurs. The interview with each patient lasted an average of 30 minutes.
Study: NCT04923061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure group
Description: In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study: NCT06488079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient-specific label
Description: The NutrInform Battery Front-of-Pack nutritional label

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No label
Description: Conventional food educational flyer
Study: NCT05544643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Extended Mio 30 Infusion Set
Description: Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Extended Mio 30 Infusion Set
Description: Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
Study: NCT06092697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed PEEK restorations
Description: Indirect dental restoration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed PEEK restorations
Description: Indirect dental restoration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed PEEK restorations
Description: Indirect dental restoration
Study: NCT06214754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment
Study: NCT05899387

Intervention type: PROCEDURE
Intervention: Seroma punction
Description: Puncturing of a seroma in case of occurence and clinical need

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at defined time points according to protocol

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at defined time points according to protocol

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at defined time points according to protocol

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at defined time points according to protocol
Study: NCT06066203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-035
Description: GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
Study: NCT05989490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
Study: NCT06290947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR Cuffs for Intervention Group
Description: The intervention consists of supervised treadmill sessions incorporating specialized BFR cuffs, branded as H+ Curve, tailored for Blood-Flow Restriction Walk Training (BFRw). These cuffs are strategically positioned on the upper portion of the lower limbs to induce muscle adaptations and~improve metabolic health outcomes. The innovative protocol is designed to probe the potential benefits of BFRw in ameliorating insulin sensitivity and enhancing aerobic capacity, thus presenting a pioneering exercise approach for individuals with Type 2 Diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Walking Training Program
Description: The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Walking Training Program
Description: The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention.
Study: NCT05845645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
Study: NCT06386237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)
Description: Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)
Description: Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
Study: NCT04909541

Intervention type: OTHER
Intervention: CEGSSS-Canadian Endourology Group Stent Symptom Score
Description: Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
Study: NCT04254640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Injection
Description: Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclarubicin
Description: aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
Study: NCT05339646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 1~7 and Ritonavir
Description: Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 8~9
Description: Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 10~12 and ritonavir
Description: Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 13 and Ritonavir
Description: Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date
Study: NCT05581745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood group A2 donor to blood group O recipient lung transplant surgery
Description: Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
Study: NCT05339646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 14 and Ritonavir
Description: Cohort 11: to be decided
Study: NCT06090786

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRD assessment
Description: Bone marrow withdrawal for MRD quantification
Study: NCT05475405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapulothoracic mobilization
Description: Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius
Study: NCT04910555

Intervention type: OTHER
Intervention: strong desire to void - cognitive task
Description: Strong desire to void - cognitive task (verbal fluency)
Study: NCT05985512

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
Study: NCT06546384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Treatment with liraglutide, following standard clinical practice as per below schedule:~Week 1: Injected dose of 0,6 mg once daily Week 2: Injected dose of 1,2 mg once daily Week 3: Injected dose of 1,8 mg once daily Week 4: Injected dose of 2,4 mg once daily From week 5 onwards: Injected dose of 3,0 mg once daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction recommendations (nutritional and exercise)
Description: Participants will receive nutritional and exercise recommendations and 2 telephone consultations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight reduction recommendations (nutritional and exercise)
Description: Participants will receive nutritional and exercise recommendations and 2 telephone consultations
Study: NCT06014528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100mg QD orally (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of IN10018
Description: 100mg QD orally (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin
Description: 40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: 40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
Study: NCT05043064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet lab tasks
Description: Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet lab tasks
Description: Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet lab tasks
Description: Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model